"10.1371_journal.pone.0069748","plos one","2013-08-06T00:00:00Z","Lucia B Jilaveanu; Fengmin Zhao; Christopher R Zito; John M Kirkwood; Katherine L Nathanson; Kurt D'Andrea; Melissa Wilson; David L Rimm; Keith T Flaherty; Sandra J Lee; Harriet M Kluger","Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, United States of America; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America; Department of Biology, School of Health and Natural Sciences, University of Saint Joseph, West Hartford, Connecticut, United States of America; Pittsburgh Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, United States of America; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States of America","Conceived and designed the experiments: LBJ CRZ JMK KLN KD MW DLR KTF HMK. Performed the experiments: LBJ CRZ KD MW. Analyzed the data: FZ SJL. Contributed reagents/materials/analysis tools: KTF JMK. Wrote the paper: LBJ FZ SJL HMK.","Dr. Rimm serves as a consultant for a company called HistoRx that has licensed the technology for automated analysis used in this study. Dr. Flaherty serves as a consultant to Bayer and Onyx Pharmaceuticals, the developers of sorafenib. In addition, the authors confirm that this does not alter their adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Lucia B Jilaveanu","LBJ",11,TRUE,9,4,2,4,TRUE,FALSE,FALSE,0,NA,FALSE
